Welcome to our dedicated page for 180 Life Sciences news (Ticker: ATNF), a resource for investors and traders seeking the latest updates and insights on 180 Life Sciences stock.
ETHZilla Corporation, formerly 180 Life Sciences Corp. (ATNF), reports developments tied to its transition from a biotechnology and iGaming-focused issuer into a public-company Ethereum treasury vehicle. Recurring updates cover ETH accumulation, treasury financing, convertible notes, private placements, common stock and warrant ticker changes, and the company’s on-chain yield strategy with Electric Capital as external asset manager.
Company news also covers legacy operating matters, including biotechnology intellectual property in areas such as neuroinflammation, fibrosis and post-operative cognitive dysfunction, as well as the Technology Gaming Platform associated with the company’s iGaming strategy. Capital-structure actions, share repurchases, governance changes and strategic updates remain recurring disclosure themes.
180 Life Sciences Corp. (NASDAQ: ATNF) announced a private placement to raise approximately $11.7 million by issuing 2,564,000 shares of common stock at a price of $4.55 each, along with warrants. The exercise price for the warrants is $5.00, and they will expire in five years. Closing is expected on February 23, 2021. The offering targets accredited investors and includes a commitment to file registration statements with the SEC for resale of the shares and warrants.
180 Life Sciences Corp. (NASDAQ: ATNF) announced its participation in the H.C. Wainwright Bioconnect 2021 Conference, with on-demand presentations available between January 11-14, 2021. The clinical-stage biotechnology company focuses on developing novel drugs for inflammatory diseases, fibrosis, and pain, currently leading Phase 2b/3 trials targeting anti-TNF therapies. The presentation will be accessible via the company's website for up to 90 days post-conference.
180 Life Sciences Corp. (NASDAQ: ATNF) announced its participation in the LD Micro Virtual Main Event 2020 Conference on December 15, 2020, featuring CEO Dr. James Woody's presentation at 1:40 PM EST. The company focuses on developing drugs for inflammatory diseases, fibrosis, and pain, with its lead program currently in Phase 2b/3 trials. Their unique format includes 10 minutes of presentation followed by a 10-minute Q&A session. For registration, visit the specified link.
180 Life Sciences Corp. (NASDAQ: ATNF) announced its Nasdaq opening bell ceremony on November 27, 2020, celebrating its recent IPO. CEO Dr. James Woody and the team will participate virtually, emphasizing the company's focus on developing novel drugs for inflammatory diseases, fibrosis, and pain. The lead program is in Phase 2b/3 trials, leveraging expertise from renowned institutions. This milestone marks the company's transition to public status, showcasing its commitment to addressing unmet medical needs.
180 Life Sciences Corp. (NASDAQ: ATNF) has expanded its intellectual property (IP) portfolio, focusing on treatments for inflammatory diseases, fibrosis, and pain. The company now holds 16 patent families with 42 issued patents and 32 pending applications across key markets such as the U.S., Canada, Europe, and China. Recent developments include a notice from the USPTO about a new patent application for a method treating frozen shoulder and the acceptance of a patent for early-stage Dupuytren's Disease. Additional patents have been granted in the EU, enhancing its market presence.
180 Life Sciences Corp. (NASDAQ: ATNF) announced a successful merger with KBLM Merger Corp IV, marking its transition to a stand-alone public entity. CEO Dr. James Woody aims to leverage the expertise of a seasoned management team to advance the company's drug pipeline, focusing on unmet medical needs in inflammatory diseases, fibrosis, and pain. Key programs include a Phase 2b/3 trial for Dupuytren's contracture and pre-clinical efforts on synthetic cannabidiol analogs. The company intends to maintain low operating expenses through grant funding.
180 Life Sciences Corp. (NASDAQ: ATNF) has announced the successful closing of its merger with KBL Merger Corp IV, officially becoming a publicly traded company on Nasdaq. The company focuses on developing novel drugs for unmet needs in inflammatory diseases, fibrosis, and pain. With a robust pipeline, its lead program in Phase 2b/3 targets Dupuytren's contracture, affecting over 15 million Americans. The leadership team includes notable experts such as Dr. James Woody and Prof. Sir Marc Feldmann, with expectations for significant advancements in therapeutic solutions.